Study of TAK-672 in Participants With Acquired Hemophilia A

Inclusion Criteria

• •1. Male or female Japanese participants of \>=18 years of age.
• •2. Participants who (or their legally authorized representatives) have provided his/her written informed consent form prior to any study-related procedures and study product administration.
• •3. Participants with a diagnosis of AHA based on clinical evaluation and supportive local laboratory testing as shown below:
• •* Presentation with spontaneous bleeding without anatomical cause and without prior known bleeding disorder.
• •* Prolonged activated partial thromboplastin time (aPTT) without explanation.
• •* Abnormal aPTT cross mixing test consistent with FVIII inhibitors
• •* Confirmation of a low FVIII:C.
• •* Positive FVIII inhibitor (\>=0.6 BU) as measured either in the local or central laboratory
• •4. Participants with a severe bleeding episode which the investigator finds necessary to treat and whose severe bleeding episode meets at least 1 of the following criteria:
• •* Bleeds that pose a threat to a vital organ that could threaten life (e.g. intracranial bleed, or any site that could obstruct the airway).
• •* Bleeds that pose a threat to a vital organ where life is not threatened but the organ function could be impaired (e.g., intraspinal bleed threatening the spinal cord and/or nerve conduction; a continual bleed into the kidney or bladder that could result in an obstructive uropathy, testicular bleed, bleed in and around the eye).
• •* Bleeds requiring a blood transfusion to maintain the Hgb level at above-life or organ threatening levels (e.g. post-surgical, gastro-intestinal, retro-peritoneal, and thigh bleeds).
• •* Intramuscular bleeds where muscle viability and/or neurovascular integrity is significantly compromised or at risk of being compromised.
• •* Intra-articular bleeds impacting a major joint associated with severe pain, swelling and severe loss of joint mobility (reduced \>70%) or where a bleed could result in joint destruction (e.g. in and around the femoral head).
• •5. Participants who are taking anti-thrombotics (including anti-platelet agents and anticoagulantswith confirmatory laboratory testing documenting specific FVIII inhibitor titer and with 3 half-lives of the agent have elapsed since the last dose.
• •6. Participants with expected life expectancies of at least 90 days prior to the onset of the hemorrhagic episode.
• •7. Participants of reproductive age who have agreed to use acceptable methods of contraception and if female, undergo pregnancy testing as part of the screening process.
• •8. Participant who are able to willing and able to comply with the requirements of the protocol.